Dr. David D. Kandath, MD
Cardiology (Cardiovascular Disease Physician)
- Medicare participating
At a glance
- Years since graduation
- 45
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 766
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
NY license 162533 -
Specialist
NY license 162533
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- St Peter's Hospital Albany, NY
- Saratoga Hospital Saratoga Springs, NY
- Glens Falls Hospital Glens Falls, NY
- Ellis Hospital Schenectady, NY
- St Marys Healthcare Amsterdam, NY
Medical groups
- St. Peter's Health PArtners Medical Associates, P.c. (487 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 766
- Services billed
- 4,621
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 1,039 | 586 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 537 | 447 |
| Injection, regadenoson, 0.1 mg | 332 | 82 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 275 | 245 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 226 | 29 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 199 | 188 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 180 | 95 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 164 | 154 |
| Blood test, clotting time | 160 | 23 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 131 | 47 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Rosuvastatin Calcium Other prescribers in Saratoga Springs, NY | 1,628 |
| Ezetimibe Other prescribers in Saratoga Springs, NY | 757 |
| Eliquis (apixaban) Other prescribers in Saratoga Springs, NY | 692 |
| Carvedilol Other prescribers in Saratoga Springs, NY | 370 |
| Spironolactone Other prescribers in Saratoga Springs, NY | 341 |
| Clopidogrel (clopidogrel bisulfate) Other prescribers in Saratoga Springs, NY | 304 |
| Torsemide Other prescribers in Saratoga Springs, NY | 296 |
| Ozempic (semaglutide) Other prescribers in Saratoga Springs, NY | 277 |
| Losartan Potassium Other prescribers in Saratoga Springs, NY | 250 |
| Pravastatin Sodium Other prescribers in Saratoga Springs, NY | 244 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 17 payments worth $243 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $190 |
|---|---|
| Amgen Inc. | $30.37 |
| Altathera Pharmaceuticals LLC | $22.76 |
| Food and Beverage | $243 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 5 companies. The companies reported $408,928 in research payments for these studies, mostly to the institutions running them.
- A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
Eli Lilly and Company · Active, not recruiting · NCT06292013 - HPS-4/TIMI 65/ORION-4: A Double-blind Randomized Placebo-controlled Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Atherosclerotic Cardiovascular Disease
Novartis Pharmaceuticals Corporation - The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Eli Lilly and Company · Active, not recruiting · NCT06383390 - A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
Amgen Inc. - A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with establish…
Boehringer Ingelheim Pharmaceuticals, Inc. - A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or O…
Amgen Inc. - A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with establish…
Boehringer Ingelheim International GmbH - A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a)
Amgen Inc. - A master protocol to investigate the efficacy and safety of orforglipron once daily in participants with hypertension and obesity or overweight: randomized, double-blind, placebo-controlled trials (attain-hypertension…
Eli Lilly and Company - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in p…
Boehringer Ingelheim International GmbH
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.